Category: Jefferies
-
Clorox stock upgraded by Jefferies as topline growth improves By Investing.com
•
On Tuesday, Jefferies upgraded Clorox (NYSE:) stock to buy from hold, setting a new price target of $187, up from the previous price of $174. The company highlighted the positive outlook for the company’s future performance, anticipating a return to historical levels of growth and profitability. Clorox, known for its…
-
Manchester United brand remains strong despite recent financial losses: Jefferies By Investing.com
•
Investing.com – Despite recent financial challenges, Manchester United Liverpool Football Club (London:) (NYSE:)’s brand remains resilient and strong. According to analysts at Jefferies, the club’s global recognition and extensive fan base remain the key drivers of its strength, even amid declining financial performance and rising operating costs. Manchester United have…
-
Trump win could challenge IRA policies, says Jefferies By Investing.com
•
A Trump victory in the 2024 US presidential election could put the Inflation Reduction Act (IRA) at risk, according to an analysis by Jefferies. The report noted concerns about potential declines in support for renewable energy if Trump returns to office, especially since Republicans are expected to control the Senate.…
-
Green Plains rated Buy at Jefferies, seeing likely H2 rebound for ethanol margins
•
JJ Gouin/iStock via Getty Images Green Plains (NASDAQ:GPRE) gets a Buy rating and a $28 price target from Jefferies, which says it expects to see profitability return for ethanol producers over the rest of this year, given expected North American corn yields and lower Corn and natural gas prices. Green…
-
Inozyme stock draws Buy at Jefferies (NASDAQ:INZY)
•
Leo Patrizi Inozyme Pharma (NASDAQ:INZY) traded higher on Tuesday after Jefferies assumed coverage with a buy rating and a $17 price target, citing three rare disease opportunities for the company’s flagship asset, INZ-701. Enzyme replacement therapy is currently undergoing clinical trials. Studies on ENPP1 deficiency, calcification, and pseudoexfoliative ectodermal tumor…
-
Jefferies says AI is already a bubble. But the bubble will likely get bigger By Investing.com
•
The AI bubble is likely to get bigger before it deflates, analysts at Jefferies said in a recent note. Since ChatGPT’s introduction, the market cap of a select group of 27 large-cap AI stocks has surged by nearly $10 trillion, a 127% increase. However, this growth stands in stark contrast…
-
Consumers are adopting a “wait-and-see” approach says Jefferies By Investing.com
•
Despite strong investor interest in AI-enabled smartphones, consumers are adopting a “wait and see” approach, Jefferies analysts said Thursday. The investment bank believes that consumers are not yet completely excited about AI features on smartphones, likely because they are unsure of what AI can offer, its cost, and ease of…
-
Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference By Investing.com
•
Washington, May 30, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (NASDAQ:) Vanda (Nasdaq: VNDA) announced today that the company will participate in the Jefferies 2024 Global Healthcare Conference in… New York City on Thursday, June 6, 2024. A corporate presentation is scheduled 2:00 PM EST. The company’s presentation at the Jefferies…
-
Jefferies starts AZZ Inc. stock with Buy, highlights growth from reshoring and infrastructure By Investing.com
•
On Monday, Jefferies initiated coverage on NYSE:AZZ (NYSE:), AZ Company . stock, with a Buy rating and a price target of $105.00. The company highlighted the position of AZZ Inc. As the leading independent supplier of metallic coatings in North America, it believes it is well positioned to capitalize on…